Future Synthetic Drugs of Abuse
Donald A. Cooper
Drug Enforcement Administration
It seems likely that primitive man wished at times to escape his reality and most probably found some natural drug to facilitate this desire. In fact, abuse of the coca leaf and the opium poppy is thought to have been practiced for at least the last 3400 years (Lathrap 1976; Rosengarten 1969) and the use of peyote may have been known as early as 1000 BC (Schultes 1938; 1940). Perhaps due in part to the long history of opiate products, one of the first derivatives of a natural drug to be used pharmaceutically was heroin. The acceptance of heroin as a pharmaceutical was primal in establishing the concept that certain structural modifications of physiologically active compounds can result in new compounds which cause biological responses which are not only similar, but are enhanced as compared to those of the parent compounds. Other works such as the structural elucidation of mescaline and the preparation of N-methyl and N-acetyl derivatives of mescaline has served to strengthen this concept and to broaden the scope of permissible derivatives (Spath 1919). In the ensuing years much knowledge has been gained regarding biologically useful derivatives of the naturally occurring drugs but, most importantly, the structures of the alkaloids and the protoalkaloids have, one by one, been elucidated. This knowledge has then allowed researchers of recent times to deduce many of the structure relationships associated with specific biological responses. The sum of this hardwon nowledge allows one to produce pharmaceutically useful compounds, which have no counterpart in nature, from off the shelf chemicals. Unfortunately there are those people who would take this body of knowledge and, rather than use it for the enhancement of medical science, use it for their own financial gain. Individuals such as these have created the so-called designer drug phenomenon.
Henderson (1986) first described a synthetic drug as one which was designed by a clandestine chemist to produce a certain pharmacological response. However, today designer drugs are universally understood to belong to a group of clandestinely produced drugs which are structurally and pharmacologically very similar to a controlled substance but are not themselves controlled substances (Langston and Rosner 1986). The Drug Enforcement Administration (DEA) has noted that the designer drug terminology tends to cast a somewhat glamorous aura onto the concept, and as a result, the DEA feels that it would be wise to refer to these compounds in some other manner and suggests the use of the term Controlled Substance Analogs (CsA).
In October of 1987 the United States Government amended the Controlled Substance Act in an effort to curtail the illicit introduction of new CsA's. This amendment states that any new drug which is substantially similar to a controlled substance currently listed under the Code of Federal Regulations (CFR), Schedule I or II, and has either pharmacological properties similar to a Schedule I or II substance or is represented as having those properties, shall also be considered a controlled substance and will be placed in Schedule I. The amendment further contains provisions which exempt the legitimate researcher as well as compounds that are already being legally marketed from the provisions of the amendment.
Since the CsA amendment has yet to be tested in a court of law, it is much too early to say how successful it will be in limiting the spread of the CsA phenomena. However, it is safe to assume that there will be those who believe that they can manage to evade the provisions of the CsA amendment, and much of the world has not yet even attempted to find a litigious solution to the problem of CsA's. Therefore, an attempt to identify those CsA's which would be logical candidates for synthesis by a clandestine chemist is still a pertinent exercise.
A great many compounds, when taken in sufficient quantity, will alter one's perception of reality. For the purposes of this paper, the term hallucinogen is reserved for those compounds that are characterized by the predominance of their actions on mental and psychic functions (Brown 1972).
Hallucinogens can be classified according to structural similarities into four groups of compounds and into one group containing miscellaneous structures. The classifications are: indoles, phenylalkylamines, piperidyl benzilate esters, cannabinoids and miscellaneous.
The piperidyl benzilate esters have been extensively studied and relationships between psychotomimetic activity and chemical structure have been established (Abood et al. 1959; Abood and Biel 1968). The N-methyl and N-ethyl-3-piperidyl benzilate esters are controlled substances and are listed under the CFR Schedule I as hallucinogens. Benactyzine is a noncontrolled drug which is used medically as an antagonist to cholinergic nerve fibers (Biel et al. 1962). It appears that the pharmacological effects of the piperidyl benzilate esters may not be conducive to a good trip for the user. Brown describes the pharmacological effects by explaining how thought processes are severely disrupted. He reports that speech is disorganized and incoherent, and that confusion, disorientation, and amnesia occur often and may be long lasting (Brown 1972). Perhaps these compounds should not be classified as hallucinogens but rather as incapacitating agents. Additionally, although the pharmacological effects of the piperidyl benzilates have been compared to those elicited by phencyclidine (Shulgin 1969), there is no evidence to suggest any significant abuse of these compounds. Therefore, no further discussion will be given to the piperidylbenzilate esters.
Given the world wide ready availability of marijuana, it is somewhat difficult to produce a viable argument for making CsA's of cannabinoids. However, ten years ago (1978) an attempt to produce CsA's from cannabis extracts was encountered in the Jacksonville, Florida area. In this case a concentrated extract of cannabis had been obtained by a soxhlet extraction. The extract had been acetylated with acetic anhydride, and in the final step, the excess acetic anhydride removed by distillation (reference is unretrievable due to its appearance in an underground periodical). The product contained neither quantities of nonderivatized cannabinoid nor any identifiable plant fragments. Since this single instance, no acetalaced cannabinoid samples have been reported by a DEA laboratory. Therefore, this instance is assumed to represent an isolated occurrence and as such, will serve to terminate our discussion of cannabinoid CsA's.
Under the heading miscellaneous, one must include nearly any ingestible compound known to man, as any substance taken at toxic levels will alter one's perception of reality. Obviously a discussion of all such compounds as models for CsA hallucinogens is not within the scope of this article. However, the compound known as phencyclidine (PCP or N-(1-phenylcyclohexyl)piperidine), although developed by Parke Davis and Company (Rochester, Michigan) as an anesthetic, does produce psychotomimetic effects and is widely abused in the United States. It is listed in the CFR under Schedule II, and two of its homologs and one analog are listed under Schedule I.
Therefore, in the following discussions, the indoles, the phenylalkylamines and PCP will be considered as possible candidates for hallucinogenic CsA's.
The literature covering indole chemistry is huge and diverse. Over 500 naturally occurring indole alkaloids were known by 1972 and accounted for nearly one fourth of all alkaloids known at that time (Robinson 1968). By 1980, the number of known indole alkaloids had risen to approximately 1200 (Kisakurek and Hesse 1980). Today there have been many more indoles added to the list of naturally occurring alkaloids. These alkaloids include such pharmacologically and structurally diverse compounds as tryptophan (essential amino acid), reserpine (tranquilizer), strychnine (stimulant-convulsant), harmaline (hallucinogen), serotonin (anticholinesterase-monoamine oxidase inhibitor), ergometrine (oxytocic), vinblastine (antitumor agent), and psilocybin (hallucinogen).
Only nine compounds containing the indole nucleus are controlled substances under the United States Federal Statutes. Three of these compounds are classified as ergot alkaloids, five are simple 3-(2-ethylamino)indoles, and one is the pentacyclic alkaloid, ibogaine. The ergot alkaloids are lysergic acid, lysergic acid amide, and lysergic acid diethylamide (LSD). The five controlled indolealkylamines are N,N-dimethyltryptamine (DMT), N,N-diethyltryptamine (DET), N,N-dimethyl-5-hydroxytryptamine (bufotenine), N,N-dimethyl-4-hydroxytryptamine (psilocin), and the phosphate ester of N,N-dimethyl-4-hydroxytryptamine (psilocybin).
Because the major pharmacological effects of ibogaine are probably not those of a hallucinogen (Schneider and Siggs 1957; Turner et al. 1955; Wooley 1962) and because only a very few illicit samples have been encountered, we will not discuss the subject further.
Lysergic acid (compound 1, Figure 1) is a tetracyclic compound, and as noted previously, contains an indole nucleus and belongs to the family of ergot alkaloids. Nearly all of the known naturally occurring hallucinogens have a 3-(2-ethylamino)indole contained within the molecular structure.
The assessment of a particular LSD derivative as a candidate for a future CsA involves the consideration of several points. The most important are those attempts made by other researchers to modify the structure of LSD while retaining hallucinogenic activity. To date, all attempts to modify the tetracyclic ring system have resulted in a loss of hallucinogenic activity. For instance, of the four possible C-8 stereoisomers only the dextro isomer of LSD is hallucinogenic (Rothlin 1957a). Modification of the amide alkyl substituents also reduces hallucinogenic activity substantially (Usdin and Efron 1972). Additionally, substitution with either a hydroxyl or a methoxy at the C-12 of LSD results in a compound with no hallucinogenic activity (Usdin and Efron 1972), whereas a comparably substituted methoxyindolealkylamine appears to always be hallucinogenic (Gessner and Page 1962). The only structural modification which results in the maintenance of hallucinogenic activity on par with LSD is the substitution of either a methyl or an acetyl to the indole nitrogen (Rothlin 1957b).
The total synthesis of LSD derivatives is not simple and requires the talents of an adept synthetic chemist (Jacobs and Craig 1934; Kornfeld et al. 1954; Garbrecht 1959). Much of the LSD produced today uses ergotamine that is obtained from legitimate commercial sources (Golden, L. personal communication). However, if ergotamine becomes difficult to obtain from commercial sources, the ergot alkaloids can be produced easily and in large quantities by cultivating strains of the fungus Claviceps in submerged cultures (Spalla 1980). Given the fact that structural modifications of the tetracyclic ring system are likely to result in a product with either little or no activity, and the fact that there will never be a shortage of ergot alkaloids for clandestine syntheses, it is quite unlikely that the total synthesis of LSD or derivatives thereof will become commonplace in the near term. One final point to consider is that the CFR lists LSD and all optical, geometrical, and positional isomers of LSD under Schedule I, and Iysergic acid and lysergic acid amide under Schedule III.
Because of previously noted pharmacodynamics and the imposing nature of a total synthesis, the immediate precursor of a LSD derivative synthesis will most certainly be a controlled substance, namely Iysergic acid; therefore, much of the impetus for producing noncontrolled LSD derivatives is lost. However, if the CsA amendment were not a consideration there would be a clear first choice via substitution of the indole nitrogen to create either 1-alkyl or 1-acyl derivatives. Derivatives of this type most probably fall under the purview of the CsA amendment. The N,N-methylpropyl isomer of LSD has been the only derivative of LSD examined by the author. Derivatives of this type might seem to be an unlikely choice for a CsA due to a high probability of significant loss in hallucinogenic activity. However, a reduction in hallucinogenic activity may become acceptable to the U. S. clandestine chemist when he notes that lysergic acid amide is listed as a Schedule III substance in the CFR; therefore, structurally similar substances of this compound are exempted from the CsA amendment. A lucid argument can then be made that lysergic acid N,N-dimethylamide is derived from lysergic acid amide rather than LSD. Carrying this theme to the next logical step one would then assume that the 1-alkyl and 1-acyl derivatives of the N,N-dimethyl isomer would also not be controlled by the CsA amendment. At present, no known CsA of LSD has ever been encountered by the DEA.
All of the hallucinogenic indolealkylamines can be classified as belonging to the family of compounds known as tryptamines and are substituted 3-(2-ethylamino)indoles (compound 2, Figure 2).
The tryptamines are a most interesting and biologically useful class of compounds. In the human body, serotonin (5-hydroxytryptamine) functions as a vasoconstrictor, inhibits gastric secretion, stimulates smooth muscle, and is naturally present in the central nervous system where it is involved in neurotransmission (Goodman and Gilman 1970). The 5-methoxy homolog of serotonin is considered to be hallucinogenic in humans as is the 5-methoxy homolog of gramine (3-(N,N-dimethylaminomethyl)indole) (Gessner et al. 1961). Melatonin (N-acetyl-5-methoxytryptamine), formed by the mammalian pineal gland, appears to depress gonadal function and is known to cause contractions of melanophores. Bufotenine, the N,N-dimethyl homolog of serotonin, is classified as a very weakly active hallucinogen and is noted to have extremely unpleasant cardiovascular depressive side effects (Holmstedt et al. 1967). The O-methyl homolog of bufotenine, N,N-dimethyl-5-methoxytryptamine (5-methoxy-DMT), is reported to be an extremely potent hallucinogen, but it, like all other C-5 substituted indolealkylamines, is not active if taken by mouth (Brown 1972). Both DMT and DET are well known for their hallucinogenic activity, just as both of these compounds are also inactive if taken by mouth. The N,N-dipropyl and diallyl derivatives are also hallucinogenic only if used either parenterally or by inhalation at approximately the same level as DET, whereas higher homologs abruptly become inactive (Szara and Hearst 1962). The compound 6-hydroxy-DET has been determined to be a major metabolite of DET in man (Szara et al. 1966), and it does not possess hallucinogenic activity (Szara 1970). Conversely, the 4-hydroxy-N,N-dimethyltryptamines (psilocin and psilocybin), are very active hallucinogens when taken orally. The activity of psilocybin (O-phosphoryl-4-hydroxy-DMT) when taken by mouth is not related lo the phosphoric acid radical since the pharmacological effects of psilocin (4-hydroxy-DMT) are identical (Horita and Weber 1961). Pharmacological information for baeocystin (4-hydroxy-N-methyltryptamine) was not found; however, one would expect hallucinogenic activity to parallel that of the N-alkyl-tryptamines and thereby would expect the drug to be weakly hallucinogenic.
It is thought that in the past most clandestine syntheses of indolealkylamines used indole as the starting material (Speeter and Anthony 1954). A modest literature search will convince a clandestine chemist that the use of the Fischer indole synthesis affords access to a greater variety of indole derivatives (Huisgen and Lux 1960; Robinson 1983) as it will also reduce the chance that law enforcement will be alerted by his purchases of essential chemicals. Hence, in the production of indolealkylamine derivatives, the covert chemist need not be limited by the commercial availability of appropriate indole precursors.
Relative to those which lack an aryl ring substitution, there is no doubt that the activity of psilocybin/psilocin upon ingestion is due to an enhancement of gastrointestinal absorption which, in turn, must be structurally related to the presence of the C-4 hydroxyl substitution. Therefore, if the CsA amendment were not a consideration, derivatives derived from psilocin would be the obvious first choice. These derivatives are the 4-hydroxy-N,N-alkyl homologs starting with N,N-dimethyl, N,N-methyl-ethyl, and on to N,N-diallyl to give a total of 10 possible derivatives. As is also the case for hallucinogenic phenylalkylamines, alkyl substitution, not to exceed a C-3 moiety, at the position alpha to the side chain nitrogen generally will maintain hallucinogenic activity. This brings the total possible number of hallucinogenic CsA's of psilocin to 40. A somewhat removed second choice would be the same series of derivatives in conjunction with either acetylation or methylation of the indole nitrogen. This would then bring the total number of the possible 4-hydroxy substituted tryptamine CsA's (less one for psilocin) to 119.
The 5-methoxy derivatives of gramine and serotonin are first choices for future CsA's when considering the new U. S. amendment. Substitution at the alpha carbon on the side chain will probably maintain psychotropic activity only for serotonin derivatives. Hence, allowing only a methoxy substituent at the aryl C-5 position, and a substitution at the carbon alpha to the nitrogen (the nitrogen being any combination of hydrogen, methyl, ethyl, n-propyl, and allyl) 75 CsA's can be obtained. Then substitution of the indole nitrogen with either methyl or acetyl brings the total number of possible CsA's that can be argumentatively related to serotonin to 225.
An additional series of compounds that could serve as future CsA's under U. S. law are those which are substituted with alkyl groups at the carbon alpha to the side chain nitrogen. Recently, a commercially available tryptamine which has an ethyl moiety substituted at the alpha carbon has become the newest U.S. tryptamine CsA. Known as ET in the illicit CsA drug market is 3-(2-amino-butyl)indole (etryptamine, monase by Upjohn (Kalamazoo, MI); compound 3, Figure 3). Because ET does not appear in either Schedule I or II of the CFR and is a legally marketed product, ET and derivatives thereof are exempted from control under the CsA amendment. Pharmacokenitic data on ET indicates that it is a monoamine oxidase inhibitor (Govier et al. 1953; Klein and Davis 1969) and psycho-energizer (Robie 1961; deHaen 1964). Hence, ET could produce some degree of hallucinogenic activity in man. In 1986 ET was reported as the she causative agent in a fatal overdose in Duesseldorf, Germany (Daldrup et al. 1986). This may be one of the few times that a CsA has originated outside of the U. S. The sample of ET which was submitted to our laboratory appears to have been obtained from the Aldrich Chemical Company ($48.05/100 gm; Milwaukee, WI). Unfortunately, it is not yet clear if ET is actually the substance which is producing the biological response being sought by the illicit user. It is the case that the sample of ET we examined and the batch of ET which the Aldrich Chemical Company is presently selling contains a major quantity (about 30%) of the agent shown in Figure 4 which could also be a hallucinogen (Turner 1963; Naranjo 1967).
Nomenclature for this possible hallucinogen can either be 1-methyl-3-ethyl-1,2,3,4-tetrahydro-harmane, or 2,2-dimethyl-4-ethyl-2,3,4,5-tetrahydro-[beta]-carboline. The creation of this substance most probably occurred after synthesis and during the purification of ET. Under anhydrous conditions, the reaction of acetone and ET would give the correponding enamine which could then undergo a Mannich condensation to yield the hallucinogen (Whaley and Govindachari 1951; Shoemaker et al. 1979). The compound 2-methyl-8-methoxy-4,5-dihydro-[beta]-carboline (harmaline) is considered to be a hallucinogen (Hochstein and Paradies 1957) as well as a monoamine oxidase inhibitor (Burger and Nara 1965). On the other hand, the compound 2-methyl-8-methoxy-2,3 4,5-tetrahydro-[beta]-carboline is classified as a tranquilizer (Usdin and Efron 1972). We were not able to attain any literature whatsoever on the hallucinogen shown in compound 4 (Figure 3), much less any pharmacokenetic data. Hence, due to the apparently unpredictable pharmacological behavior of structurally similar [beta]-carboline derivatives, I will not speculate as to the pharmacological properties of said substance.
As was observed for the simple indole alkaloids, there are several simple phenylalkylamines which play important roles in the normal biological function. Some of these are tyrosine, 3,4-dihydroxyphenylalanine (DOPA), 3,4-dihydroxytryptamine (dopamine), and norepinephrine. The naturally occurring hallucinogenic protoalkaloid, mescaline, is 2-(3,4,5-trimethoxyphenyl)ethylamine. Structural modifications which impart hallucinogenic activity to phenylethylamines have een studied and a considerable quantity of that data is easily retrieved. The following constitutes a brief review of some of the most salient concepts relative to hallucinogenic activity chemical structure relationships within the family of phenylethylamine derivatives.
It has been found that the addition of methoxy moieties to the aromatic ring of a phenylethylamine, in general, produces compounds that are psychotomimetic (Shulgin et al. 1969). Further, it has been noted that the methylenedioxy moiety can be used in the place of two adjacent ring substituted methoxy groups with C-3,4 substitution providing the most potent psychotogens (Alles 1959; Shulgin 1964; Naranjo et al. 1967; Braun et al. 1980a). Historically 3,4-methylenedioxyamphetamine (MDA) has probably been the most consistently abused psychotomimetic phenylethylamine. Amphetamine and methamphetamine are adrenomimetic at low to moderate dose levels; however, at high dose levels they also become psychotomimetic in man (Liddel and Weil-Malherbe 1953; Connell 1958). Additionally, it has been found that the addition of an [alpha]-alkyl moiety (up to C-3) (Snyder and Richelson 1970) to methoxyphenylethylamines results in an increase in hallucinogenic activity and, alkyl only substitutions to the aromatic ring tend to result in a gradual loss of central activity which can be related to the increasing size or the alkyl group (Marsh and Herring 1950; Harris and Worley 1957). Braun et al. (1980b) has determined that a gradual decrease in psychotomimetic activity also occurs with the increasing size of a N-alkyl substituent. Braun also noted that upon N,N-dialkyl substitution an abrupt and significant loss of hallucinogenic activity occurs, whereas N-hydroxy substitution maintains activity.
The bases of structure-activity relationships as determined by aromatic ring substitutions are not obvious. For instance, mescaline has relatively prominent psychotomimetic properties but 3,4-dimethoxyphenylethylamine (3,4-dimethoxydopamine) is not considered to be psychotogenic, and the hallucinogenic potency of 3,4-dimethoxyamphetamine is less than that of mescaline (Hollister and Friedhoff 1966). On the other hand, the hallucinogenic potency of 3,4-methylenedioxyamphetamine is approximately three times that of mescaline (Braun et al. 1980b). Also, tyramine (4-hydroxyphenylethylamine) is devoid of hallucinogenic activity, but 4-methoxy-tyramine is weakly hallucinogenic (Smythies et al. 1969). However, 2-methoxymethamphetamine has no known hallucinogenic activity (Usdin and Efron 1972), and the 4-methoxyphenyl-[alpha]-methylethylamine (4-methoxyamphetamine) has five limes the psychotropic activity of mescaline (Shulgin 1970). To complicate the situation further, one work reported the synthesis of 4-substituted methamphetamine derivatives using both ring activating and ring deactivating substituents of quite different atomic volumes, and found hallucinogenic activity present for all derivatives. The compounds in question are 4-bromo-, 4-amino-, 4-chloro-, 4-nitro-, 4-iodo-, and 4-hydroxymethamphetamine (Knoll et al. 1966). It is a little surprising that substituents of such radically different atomic volumes and electronegativities would all give 4-substituted- phenylisopropylamine derivatives having psychotropic activity. In contrast, another study of hallucinogenic activity as a function of aromatic ring substitution, found the compound 2,5-dimethoxy-4-methylamphetamine to be some eighty times more potent than mescaline but upon going to the 4-ethyl derivative, quite a trivial change, nearly all hallucinogenic activity was supposedly lost (Shulgin 1969). Despite these seeming inconsistencies, many of the necessary structural requirements for producing hallucinogenic phenylethylamine can be understood by noting the common structural features of these psychotogens. The structure activity relationships noted above can be found in a single source review article by Shulgin (1970).
The following phenylalkylamines are listed under Schedule I of the CFR as hallucinogens:
- 4-bromo-2,5-dimethoxyamphetamine (DOB)
- 2,5-dimethoxyamphetamine (DMA)
- 4-methoxyamphetamine (PMA)
- 5-methoxy-3,4-methylenedioxyamphetamine (MMDA)
- 4-methyl-2,5-dimethoxyamphetamine (DOM, STP)
- 3,4-methylenedioxymethamphetamine (MDMA, ecstasy)
- 3,4,5-trimethoxyamphetamine (TMA)
- 2-(3,4,5-trimethoxyphenyl)ethylamine (mescaline)
Assuming the ready availability of the appropriate chemical precursors, and assuming a lack of concern for the legal provisions enacted by governments for the purpose of controlling CsA's, choices for CsA's of ring substituted phenylethylamine psychotogens are numerous. Previously cited literature provides many such CsA possibilities with at least ten aromatic ring substituted amphetamines (compounds numbered 5-15, Figure 4) having potencies greater than mescaline (compound 5). Other CsA's can be obtained from compounds 6 through 15 by modification of the [alpha]-alkyl side chain to either C-2 or C-3 alkyls, and mono-substitution or the nitrogen with either hydroxy or short chain alkyl. These modifications result in a total Of 160 possible CsA's based only upon the ring substitutions of the aforementioned compounds. Additionally, tile ring substituted phenylisopropylamines which are presently controlled substances, can be modified in the same manner, and after excluding controlled substances and N-hydroxy MDA, there are 118 more possible derivatives, giving a total of 278 possible new CsA's. Each time a new ring substitution is introduced, such as MEM, then this number is increased by 16.
If the U. S. CsA amendment is a consideration, then psychotomimetic phenylethylamines could be created from compounds which are structurally related to dopamine, adrenaline (N-methyl-3,4-di-hydroxyphenyl-[beta]-hydroxyethylamine), and norepinephrine (3,4-di-hydroxyphenyl-[beta]-hydroxyethylamine). A case in point is the compound macromerine, N,N-dimethyl-3,4-dimethoxyphenyl-[beta]-hydroxyethylamine, a known psychotogen (Hodgkins et al. 1967). Some other compounds which could be used as CsA models are synephrine (N-methyl-4,[beta]-dihydroxyphenylethylamine), phentermine ([alpha],-[alpha]-dimethylphenylethylamine), 4-chlorophentermine, mephentermine (N,[alpha],[alpha]-trimethylphenylethylamine), phenelzine (phenylethylhydrazine), and tranylcypromine (2-phenylcyclopropylamine). Structural modifications of these compounds could provide quite a few additional CsA's. Because of the sheer size of the task, no attempt was made to determine the total number of possible CsA's that could be derived by using these compounds as models. How ever, the magnitude of the possibilities become evident when one calculates tile possible CsA's which, could be obtained using just dopamine (compound 16, Figure 5) as the model compound, as is demonstrated in the following paragraph.
The total number of possible CsA's were limited by the following considerations:
- ring substitution at C-3,4 is dimethoxy
- ring substitution to sites C-2,5,6 were limited to combinations of CH3-, Br-, Cl-, and CH3-,
- substitution on the amine nitrogen and the alpha
carbon were limited to the following:
- of the three ring sites available for substitution, no more than two were allowed for any given structure
- single substitution on the ring at C-2 to give 2,3,4-trisubstituted derivatives was disallowed
- mixed halide structures were excluded
- ring substitutions which would result in any derivative which is presently a controlled substance were disallowed.
Research targeted at the determination of structure-psychotropic activity relationships has waned in recent years. Perhaps in future years it will be the clandestine chemist who will fill in the blanks.
PhencyclidineThe synthesis of phencyclidine (PCP) was first reported in 1958 (Chen 1958) and patent rights were granted to Parke, Davis & Co. in 1960 and 1963 for medical use as an anesthetic (Parke, Davis & Co. 1960; 1963). PCP first came to the attention of DEA, then the Bureau of Narcotics and Dangerous Drugs, as a drug of abuse in the latter part of the 1960's. Pharmacologically, PCP has been described as a pseudo hallucinogen which has many of the characteristics of a depressant drug (McGlothlin 1971). Without question, PCP deserves a special niche in any discussion of drugs of abuse if for no other reason than the notoriously bizarre effects it has been known to have upon some of the abusing population (Peterson and Stillman 1978).
The now so very familiar synthesis using 1-(1-piperidyl)cyclo-hexyl carbonitrile and phenyl Grignard reagent was published by Maddox et al. in 1965 and, either fortunately or unfortunately depending upon one's point of view, the accompanying pharmacological data was useless as it could not be correlated to the compounds synthesized (Maddox et al. 1965). However, pertinent literature is not hard to find as both the original U. S. patent (Godefroi et al. 1963) and later studies have provided a pharmacological basis for the production of CsA's of PCP (Kalir and Pelah 1967; Kalir et al. 1969).
It does not appear to be possible for one to generate a CsA model structure that will not fail under the CsA amendment provision which stipulates that the term "controlled substance analogue" means a substance-the chemical structure of which is substantially similar to the chemical structure of, in this case, PCP. This is the result of the fact that a one carbon separation between an aryl system and the amine nitrogen, and the fact that the central carbon between these moieties is in a ring system appear to be principal requirements for PCP-like pharmacological activity. Other activity structure relationships are:
- substituents which decrease lipophilic character generally decrease potency
- aryl substitution with 2-thienyl generally increases potency
- substitutions onto the aryl system decreases potency
- to maintain potency N,N-dialkyl substitutions should be either piperidino or pyrrolidino ring systems
- N-ethyl is the most potent N-alkyl monosubstitution and potency falls off rapidly with either an increase or decrease in the alkyl chain size
- substitution on the beta carbon of either the cycloalkyl or the cycloalkylamino rings will most likely be synthetically difficult due to steric considerations.
Relative to medical usage, a stimulant is defined to be an agent that arouses organic activity, strengthens the action of the heart, increases vitality, and promotes a sense of well being. However, as per the medical definition, the effects produced by a stimulant may not be a very accurate term for the effects sought by those who abuse these compounds. For instance, at dose levels usually equated with heavy abuse, both amphetamine (Hampton 1961; Angrist et al. 1969) and methamphetamine (Liddel and Weil-Malherbe 1953) are thought to be psychotogenic. Therefore, several of the amphetamines could be discussed as hallucinogens; however, it seems most likely that a substantial portion of the abuse of stimulant drugs is performed with the intention of inducing a state of euphoria (Brown 1972). Historically, the abuse of stimulants (euphoriants) has been largely confined to amphetamine, derivatives thereof, and cocaine. Some of the amphetamine derivatives which have been controlled under U. S. law are methamphetamine, N-ethylamphetamine, fenethylline, phenmetrazine (preludin), phendimetrazine, benzphetamine, chlorphentermine, clortermine, diethylpropion, methylphenidate, pemoline, and amphetamine. Other derivatives of amphetamine which have been encountered in samples submitted to DEA laboratories, but have not yet been brought under legal controls, are bis-methamphetamine (compound 18, Figure 7), fencamfamine (compound 19, Figure 7) (Nied and Smith 1982), N,N-dimethylamphetamine (dimephenopan; compound 20, Figure 7) (Allen, A. personal communication), and an analog of pemoline, 4-methylaminorex (U4EUH) (compound 21, Figure 7) (Inaba and Brewer 1987). Since pemoline is listed under Schedule IV of the CFR and 4-methylaminorex is clearly an analog Of pemoline, it falls outside of the guide-lines set forth in the CsA amendment; therefore, 4-methylaminorex is not controlled under U. S. law. It is equally clear that bis-methamphetamine and N,N-dimethylamphetamine do fall under the CsA guidelines and would be considered controlled substances under tile CsA amendment. However, it may be that N,N-dimethylamphetamine may not enjoy a long history in the clandestine market as at least one work states that it is considerably less potent than methamphetamine (Schaeffer et al. 1975).
Most of the adrenomimetic activity-structure relationships were delineated in the previous discussion on psychotomimetic phenylethylamines. The principle difference between the pharmacological action, as related to structure for these two classes of compounds, is determined- by the nature of the substituents on the aryl system. In general it is noted that substituents on the aryl system which are orthopara directors tend to produce psychotogenic compounds with methoxy substituents often producing the most pharmacologically active hallucinogens. However, there are several exceptions to this general statement, not the least of which is exemplified by substitution on the phenyl ring of the electrophilic hydroxy moiety which in nearly every case either eliminates or greatly reduces hallucinogenic activity. On the other hand, adrenomimetic activity is clearly enhanced by branching of phenylethylamine at the carbon alpha to the amine nitrogen and is maintained at reasonable levels by substitution to the nitrogen as shown in table II. Both N-ethylamphetamine and N,N-dimethylamphetamine have appeared in the illicit market and clearly follow the points made above. However, a market factor has been introduced by the fact that phenyl-2-propanone (P2P) has been listed under the CFR as a Schedule II substance. Hence, it makes little sense for the clandestine chemist to produce CsA's of phenylethylamines which have potencies that are less than methamphetamine if he is going to produce his CsA's in a synthesis that uses P2P. The recent illicit use of 4-methylaminorex may well be the result of the clandestine chemist trying to circumvent the legal problems associated with P2P. On the other hand, the sum total of methamphetamine still being covertly produced suggests that the control of P2P has not appreciably reduced the drug's availability in the illicit marketplace.
As before, if the chemist is not concerned about the CsA amendment, the structural possibilities offered by Table II, less the three controlled substances that are included, provides for thirteen possible future stimulant CsA's. It would seem that the single most logical next stimulant CsA would be N-methyl-[alpha]-ethylphenylethylamine. This compound should be pharmacologically very similar to methamphetamine and synthesis could employ 1-phenyl-2-butanone instead of P2P. Alternatively, the use of 1-(4-fluorophenyl)propan-2-one, in place of P2P, would almost certainly give a product with adrenomimetic properties, and may in fact be considerably more potent than methamphetamine.
The clandestine chemist of limited chemical sophistication may not notice the structural similarity of such compounds as methylphenidate (compound 22, Figure 8), phenmetrazine (compound 23, Figure 8), 4-methylaminorex (compound 21), and amphetamine (compound 24, Figure 8). If he does recognize the constancy of the phenylisopropylamine substructure in these compounds he may well explore the literature in an effort to determine the structural outer limits for the phenylisopropylamine stimulants. At what may be near these structural outer limits he will find a class of compounds which are correctly referred to as conformationally rigid phenylethylamines. Some of the conformationally rigid phenylethylamines are fencamfamine (compound 19), tranylcypromine (2-phenylcyclopropylamine) (compound 5, Figure 9), 2-phenyl-cyclohexylamine (compound 26, Figure 9) (Smissman and Pazdernik 1973), 2-amino-3- phenyl-trans-decalin (compound 27, Figure 9), and 2-aminotetralin (compound 28, Figure 9) (Barfknecht et al. 1973). The potency of most of these compounds is highly dependent upon stereochemistry. Those isomeric forms which most closely approximate the anti periplanar conformation observed for amphetamine in solution are the most potent stimulants. Hence, transtranylcypromine is considerably more potent than is the cis isomer (Grunewald et al. 1976). The most active isomer of these compounds does not approach the potency of the simple phenylisopropylamines. Given this reduction in potency for the most active isomers one would think that, in order to obtain amiable product for the illicit market, a stereo specific synthesis would be required. This feature, along with a lowered potency for even the more active isomers, may very well exclude the conformationally rigid phenylethylamines from the synthetic repertoire of the surreptitious chemist. Hence, it is a reasonable expectation that those conformationally rigid phenylethylamines which will be abused in the future will be obtained by diversion of limit supplies rather than by clandestine syntheses.
Unfortunately, it seems to be an axiom that any compound which has any possibility of altering man's perception of himself or his surroundings will at some time be abused. Propylhexadrine, although not an extreme example, is nevertheless an example of a compound which has been abused although adrenogenic potency is far less than that of methamphetamine (Garriott 1975). Therefore, one must expect some abuse of the conformationally rigid phenylethylamines to occur. It would be my guess however, that the extent of such abuse will never be large.
The parent structure for 4-methylaminorex has been known since 1889 (Gabriel 1889) and many derivatives thereof have been studied for pharmacological activity. Pemoline (2-amino-5-phenyl-2-oxazolin-4-one) (Traube and Ascher 1913; Howell et al. 192) is presently a controlled substance in the U. S., is classified as a stimulant, and is listed under Schedule IV of the CFR. Poos (personal communication) synthesized and performend pharmacological studies for some twenty seven 2-amino-2-oxazoline isomers of which aminorex and 4-methylaminorex were two. In this work, aminorex and 4-methylaminorex, regardless of the steroisomer employed, were found to have anorectic activity on par with d-amphetamine. However, adrenomimetic activity of 4-methylaminorex was determined to be less than that of amphetamine and similar to phenmetrazine (Patil and Yamauchi 1970). It has been suggested that the effectiveness of stimulant drugs as appetite suppressants are the result of the fact that the user forgets to eat and that this behavior is in direct proportion to the adrenomimetic activity of the drug (Cutting 1969). Contrary to previously cited work this suggests that aminorex may in fact be as potent an adrenomimetic as amphetamine. In any case, Poos (personal communication) highlighted eight compounds which may have adrenomimetic activity similar to those of amphetamine and methamphetamine. Shown in Figure 10 and listed in decreasing order of anoretic activity they are compounds:
33) 2-amino-5-phenyl)-2-oxazoline [aminorex]
36) 2-amino-4-methyl-5-phenyl-2-oxazoline [4-methylaminorex]
Although not mentioned in this work, one would immediately assume that the 4-fluoro- and 4-chloro- phenyl derivatives of compounds 35 and 36 would also have significant anoretic activity.
Given the astoundingly simple synthetic process required to produce these compounds, and the fact that the 4-halogen substituted aryl derivatives would require precursors unlikely to titillate the interest of law enforcement agencies, these compounds will most probably be made in future clandestine syntheses. It is also conceivable that some enterprising clandestine chemist will wonder if appropriately substituted methoxy derivatives will have psychotomimetic properties.
The literature contain many references to stimulant drugs of variant structures which may not spark the interest of the less knowledgeable clandestine chemist. However, nearly all of these compounds can be accessed through literature searches for either derivatives of phenylethlamines or stimulant compounds. Several compounds which serve as examples are fenmetramid (Ippen 1968), prolintane, 1-([alpha]-propylphenylethyl) pyrrolidine (Heinzelman et al. 1960; Hollister and Gillespie 1970), pyrovalerone (1-(4-methylphenyl)-1-oxo-2-pyrrolidino-n-pentane) (Heinemann and Vetter 1965; Heinemann and Lukacs 1965), N,3,3-trimethyl-1-(m-tolyl)-1-phthalanpropylamine (compound 37, Figure 11)(Gill et al. 1970), zylofuramine ([alpha]-benzyl-n-ethyltetrahydro-D-threo-furfurylamine) (Harris et al. 1963), a series of N-substituted phentermine compounds (Borella et al. 1970), 4-hydroxyamphetamine (Mannich and Jacobsohn 1910; Hoover and Hass 1947a,b), N-methylephedrine (Smith 1927), nylidrin, N-(1-methyl-3-phenylpropyl)-2-hydroxy-2-(4-hydroxyphenyl-l-methyl-ethylamine (Treptow et al. 1963), pheniprazine, [alpha]-methyl-phenylethyl hydrazine (Zbinden et al. 1960), and N,N-diethyl-2-phenylcyclopropylamine (SKF). All of these compounds are derivatives of phenylethylamine with the exception of compound 37 which is a 3-phenyl-3-propylamine substituted onto a phthalane at C-1. A number of closely allied derivatives of this compound have been examined and are classified as weak stimulants.
Fenmetramide is noteworthy in that it is a 2-one derivative of phenmetrazine. Any and all of these compounds are subject to abuse; however, the synthesis of simple phenylethylamine derivatives would not appear to offer the clandestine chemist any advantage over the synthesis of methamphetamine. The reasons for this statement are that pharmacological studies have not identified other phenylethylamine structures with stimulant activity appreciably greater than methamphetamine and that either P2P or the [beta]-hydroxyphenylisopropylamines are the preferred precursors. However, in any case, the U. S. CsA amendment should apply for all compounds containing the phenylethylamine substructure.
The stimulant drugs phenmetrazine (preludin; compound 23) and methylphenidate (ritalin; compound 22) are controlled under Schedule II of the CFR. These compounds rank approximately half-way between caffeine and amphetamine in potency (Meier et al. 1954; Tripod et al. 1954a; Gruber et al. 1956). The published synthesis of phenmetrazine, which would seem to be most amenable to the clandestine laboratory, is given in the work by Otto (Otto 1956). The reaction involves the acid-catalyzed cyclization of N-hydroxyethylnorephedrine (N-hydroxyethylphenylpropanolamine). However, this reaction places severe limits on the production of CsA's because suitable precursors are limited. For instance, phenmetrazine CsA could be prepared from compounds such as N-ethyl-2,2-hydroxyphenyl-1-methylethylamine, 1,1-hydroxyphenyl-2-aminobutane, etc, but limited commercial availability would generally require synthesis of these compounds. Additionally, the product CsA would clearly be perceived, even by the untrained, as being structurally similar to phenmetrazine and thereby would be a controlled substance under the CsA amendment. Further, the corresponding phenylethylamine which could be made from these precursors, although also under the purview of the CsA amendment, would most probably have greater adrenergic activity than the phenmetrazine derivative. Hence, clandestine production of phenmetrazine CsA's would most likely be an uncommon event.
Pipradrol (compound 38, Figure 12) is a controlled substance under CFR Schedule IV and can be considered to be an analog derivative of methylphenidate. Methylphenidate can be synthesized by the method of Hartmann and Panizzon (1950). The product exists as two diastereoisomeric enantiomer pairs, one of which is the active stimulant, threo-dl-methylphenidate (Weisz and Dudas 1960), while the other is inactive as a stimulant. Threo-methylphenidate accounts for only 20% of the final reaction product (Rometsch 1958;1960). The synthesis of pipradrol may be more amenable to the clandestine laboratory as it is a relatively simple synthesis and isolation of the final product is straightforward. An appropriate C-2 substituted, N-protected piperidine is a suitable precursor for what is essentially a two step synthesis (Tilford et al. 1948; Werner and Tilford 1953). Numerous derivatives of methylphenidate and pipradrol have been synthesized with the result that structure activity relationships have been well defined (Scholz and Panizzon 1954; Tilford and Van Campen 1954; Heer et al. 1955; Fabing 1955; McCarty et al. 1957; Sheppard et al. 1960; Belleau 1960; Winthrop and Humber 1961; Portoghese and Malspeis 1961; Wilimowski 1962; Lachman and Malspeis 1962). There is little incentive, beyond the not inconsiderable pressure of an already existing and ready market, for producing clandestine CsA's of methylphenidate. However, there are a number of pipradrol derivatives described in the last cited references which are suitable for clandestine production. A best bet for a future CsA is the most potent adrenomimetic compound in this series, 2-diphenylmethylpiperidine (compound 39, Figure 12) (Tripod et al. 1954b), which is estimated to be as potent as methamphetamine (Sury and Hoffmann 1954). In a very similar article to this paper, "Drugs of Abuse in the Future," Shulgin (1975) suggested that levophacetoperane (compound 40, Figure 12) could well be a future clandestine CsA. However, this compound shares the same limitations for clandestine synthesis as does methylphenidate, in that only one diastereoisomer is active (Jacob and Joseph 1960) and it is less potent than methylphenidate (Dobkin 1960).
Although the phenylisopropylamine substructure is an integral part of most known stimulants, the well known and much abused stimulant, cocaine, does not share this structural feature. The cocaine molecule instead compares more closely to the structure of acetylcholine. The synthesis of cocaine has recently been revisited by Casale and many of the procedural techniques are explained in sufficient detail so that any competent organic chemist can now make the C-3 equatorial cocaines (Casale 1987); however, it is still a tedious and demanding synthesis, and in my opinion will only be encountered on rare occasions in clandestine laboratories. The particular pharmacological behavior of cocaine is unquestionably due in major part to the stereochemistry of the molecule as determined by the fused bicyclic tropane ring system (Clarke et al. 1973). Given the present difficulties associated with the synthesis of the tropanes and the ready availability of the natural product, it is unlikely that a synthetic CsA of this compound will appear in the near future. However, it is the case that certain modifications of natural cocaine can result in products having substantially greater potencies than cocaine. The compounds 2-carbomethoxy-3-(4-fluorophenyl)tropane and 2-carbomethoxy-3-phenylnortropane are both some 60 times more potent than cocaine (Clarke et al. 1973). These compounds could well be of interest to some clandestine chemists as taking one kilogram or cocaine and converting it into a product some sixty times more potent would obviously be quite cost effective.
In "Drugs of Abuse in the Future," Shulgin (1975) directed attention to another stimulant which also does not contain the phenylethylamine substructure and, in fact, is reminiscent of the depressant glutethimide. The compound is known commercially as bemegride, 4-ethyl-4-methylpiperidine-2,6-dione, and was first synthesized by Thole and Thorpe in 1911 (Thole and Thorpe 1911). The principal medical use is as an analeptic in barbiturate poisoning. As a stimulant, bemegride is approximately equal to phendimetrazine and pemoline in potency. Although glutethimide and bemegride are structurally similar, their pharmacokinetics are diametrically opposed. Hence, bemegride cannot be described as a CsA. Bemegride, by virtue of being a stimulant, has an obvious potential for abuse, although under the conditions of abuse, rather large quantities of the drug will be required. Increasing the possibility of bemegride abuse are the facts that the synthesis of the compound is not difficult and, of course, does not use either a controlled or watched substance as a precursor (Benica and Wilson 1950).
Depressants include such diverse chemical entities as methaqualone, 5,5-disubstituted barbituric acids, glutethimide and methyprylon, benzodiazepines, chlorhexadol, chloral hydrate, paraldehyde, meprobamate, and ethyl alcohol to name a few. Historically in the U. S., the abuse of depressants, alcohol aside, has been in major part confined to the barbiturates, methaqualone, and the benzodiazepines. Barbiturate abuse peaked in the mid 1970's and has since become near nonexistent, in part no doubt, to the well deserved bad press that the barbiturates garnered. The abuse of methaqualone peaked around 1980 and has also declined steadily since that time. However, much counterfeit "lude" is still being sold, but instead of containing methaqualone, the tablets now often contain diazepam. Diazepam has become the most prevalent depressant drug of abuse and its use is apparently continuing to rise. It is somewhat peculiar that of the many benzodiazepines known and readily available in the legal commercial market, diazepam is by far the most extensively abused. The factors controlling this apparent user preference for diazepam is certainly related, in part, to simple product recognition; however, it is my perception that the dominant factor is the ease with which the drug can be diverted from the legitimate market. In 1985 the legitimate diazepam market consisted of 5 billion tablets (Franzosa 1985) and since that time generic diazepam tablet production has increased along with even greater product availability for diversion into the illicit market (Franzosa, E. personal communication).
A typical benzodiazepine synthesis is not be considered difficult and a methaqualone synthesis is quite straightforward (Grimmel et al. 1946). Further, there is a great abundance of literature from which the clandestine chemist can draw in deciding upon a CsA based upon either the benzodiazepines or methaqualone itself. However, with the very notable exception of methaqualone, the clandestine syntheses of depressant drugs in the U. S. have been extremely rare (Franzosa, E. personal communication). It is not likely that a clandestinely synthesized benzodiazepine CsA will be encountered as long as the huge, easily diverted legitimate supplies are at hand.
The use of methaqualone (compound 41, Figure 13) is in decline, but it will be with us as an abused substance for still some time. Given the very large numbers associated with the clandestine synthesis of methaqualone, it is perhaps surprising that only two CsA's of methaqualone (compounds 42 and 43, Figure 13) have been analyzed at this laboratory. Again, past history would suggest a high probability for the appearance of new CsA of methaqualone in the future. A CsA of methaqualone will by necessity have the 3-aryl-quinazoline structure, and as a result will fall under the CsA amendment. One would shell predict that the driving force behind any future clandestine synthesis of a methaqualone CsA will revolve around attempts to use precursor materials which will not alert law enforcement to the existence of the clandestine laboratory. A literature review for CsA candidates will quickly surface several possibilities (Boissier and Piccard 1960; Camillo and David 1960; Jackman et al. 1960; Petersen et al. 1963; Boehringer Sohn 1968a,b; Sumitomo Chemical Company 1968; Hurmer and Vernin 1968; Joshi and Singh 1973; 1974). One of the most intriguing methaqualone CsA's from the perspective of a clandestine chemist would have to be the halo- and thio- derivatives described by Joshi et al. (1975). Two of the compounds from this work (compound 44 and 45, Figure 13) possess depressant activity greater than methaqualone and compound 44 would be particularly well suited to clandestine synthesis.
Literature covering the analgesics is so voluminous that a review of the published data on the subject is far beyond the scope of this work. Most of the potent analgesics are modeled after features found within the structure of morphine and some literature detailing these structural features has been published by Paul Janssen (Janssen 1960; 1961; 1962a,b; 1968). Despite a significant passage of time, the structure activity relationships established in these works still comprise a very sizable portion of our empirical knowledge on this subject.
Some 13 years ago, Shulgin (1975) provided a short overview of many of the known major classes of analgesics. The following constitutes a similar listing:
- morphinans and isomorphinans
- pethidines (meperidines), prodines, and ketobemidones
- 3,3-diphenylpropylamines (methadone, propoxyphene)
- pirinitramide derivatives
In his 1975 article, Shulgin pointed to meperidine, prodine, and ketobemidone as possible models for "Drugs of Abuse in the Future." There are some who think that Shulgin's comments were somewhat of a self fulfilling prophecy as it is felt that his article is well worn within the circles of clandestine laboratory operators (Sapienza, F. personal communication). Supporting this premise, at least to some extent, is the fact that the appearance of the first known fentanyl, China While, did not occur until 1979 (Henderson, G. 1.. personal communication). However, it is also the case that desmethylprodine (MPPP; compound 48, Figure 15) was first encountered in a DEA laboratory sample submission in July of 1973 (Kram, T. personal communication), a full two years before Shulgin published his article.
The probability that CsA's of prodine will constitute any appreciable quantity of the clandestine analgesic market in the future is relatively remote. The well publicized neuro-toxicity of the prodine dehydration product, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Langston et at. 1983; Markey et al. 1985; Fries et al. 1986; Parkes 1986), coupled with a limited scope of derivatives having appreciable analgesic activity (Berger et al. 1947; Ziering and Lee 1947; Beckett et al. 1957; Loew and Jester 1975) would seem to remove prodine from consideration as a model for CsA's. The fact that the 3-allyl analog of MPTP is not thought to be neurotoxic (Brossi 1985) and the corresponding prodine analog has greater analgesic activity than does betaprodine (Ziering et al. 1957) may be of some interest to the clandestine laboratory operator. However, allylprodine (compound 49, Figure 15) is already controlled under Schedule 1. A prodine derivative which may be found in a future clandestine laboratory is [alpha]-promedol, (Fries and Portoghese 1976). Analgesic activity for the unresolved stereoisomers of promedol is approximately ten times that of morphine, but there is some increased difficulty associated with the synthesis and neurotoxicity for it's MPTP analog is a real possibility. It is also the case that [alpha]-promedol is listed in CFR Schedule I under the name of trimeperidine.
In any event, the syntheses of prodine CsA's are fraught with considerable risk from the inadvertent production of either MPTP or an as yet unexplored congener also having neurotoxic properties. It is worth noting that at one time MPTP was tested for use as an insecticide and that there are reports of workers handling MPTP who have suffered full blown Parkinsonian symptoms (Shafer, J. personal communication).
Meperidine (pethidine, demerol; compound 50, Figure 16) is approximately 50% as potent an analgesic as is morphine and has a safety margin of only 4.8 as compared to 71 for morphine (Janssen 1985) Hence, one would assume that the continued abuse of meperidine is most probably related to the ease with which it can be diverted from commercial channels rather than it's applicability to drug abuse per se. It has been noted that there are some 4000 compounds which may be related chemically to meperidine (Burger 1970). It should be pointed out that of these 4000 compounds, many are not classified as analgesics, and they must also include the closely allied prodine and ketobemidone derivatives. The most potent analgesics of the meperidine class of compounds, as is the case with the prodine class of compounds, all appear to already be controlled under Schedule I and the less potent but clinically useful derivatives controlled under Schedule II. The most interesting compound from the view point of clandestine synthesis would have to be phenoperidine (compound 51, Figure 16) as analgesic activity is approximately 30 times that of morphine and the safety margin is increased, relative to meperidine, quite substantially (Janssen 1985). Fentanyl (compound 52, Figure 17) is an analgesic of high potency, approximately 300 times that of morphine, which was developed by Janssen in 1962 (Janssen 1962b) and is N-[(2-phenylethyl)-4-piperidyl]-N-phenyl-propanamide. The first CsA of fentanyl came to the attention of law enforcement in late 1979 but was not identified until 1981 (Allen et al. 1981). In the next three years a procession of new fentanyl CsA's appeared in the illicit drug market. The abuse of fentanyl CsA's peaked in 1985 and has since decreased dramatically (Henderson 1987), a phenomena which was the result of DEA successfully terminating the operation of the responsible laboratories. However, the ripple effect is still being felt as international and national meetings have been held to discuss the problems presented by CsA's. Also, legislation, such as the U. S. CsA amendment, has been passed in order to allow law enforcement to deal more efficiently with the analog problem.
It is the author's opinion that fentanyl CsA's will be back as the future analgesic drugs of abuse. The thoughts behind this statement are that the published synthesis schemes for the fentanyl compounds allow for the use of wide variety of precursors as discovered by the confiscated notes from an anonymous clandestine laboratory that synthesized a drug, based on information presented in two separate volumes of the Journal of Organic Chemistry (Anon. 1957; Janssen 1962a; Riley et al. 1973; Van Bever et at. 1974; Van Daele et al. 1976). Also, several fentanyl derivatives have such high potencies that the quantities required to be synthesized are trivial. For instance, carfentanil (compound 53, Figure 17) is approximately 4000 times as potent as heroin and has an extremely favorable therapeutic index (Janssen 1985). Hence, an easy week's work for two chemists could provide 10 kilograms of carfentanil which would be equivalent to 40 metric tons of pure heroin.
In the course of this article, several points have been made concerning those forces which will control the appearance of future synthetic drugs of abuse. The most important of these factors is user acceptance of the marketed drug. Needless to say, the typical clandestine drug dealer and/or chemist is not overly concerned with the health of the user. However, they are concerned with having a ready market for their product. A reputation for selling "bad stuff" would not be conducive to good business. A recent example of this can be found in MPPP.
The second most important market controlling factor is law enforcement control of the industry. A recent example would be the effects produced when P2P was placed under legal controls. The response so far has been two fold; first there has been a concerted move to either more fundamental precursors or to synthetic routes utilizing [beta]-hydroxyphenylethylamines, and second, there has been an apparent increase in the abuse of 4-methylaminorex. Hence, the methamphetamine market is in a state of flux as a direct result of law enforcement activity and either a CsA will be found which will provide both the user and the clandestine drug chemist with the same advantages as methamphetamine or a new precursor synthesis scheme will be found which will offer nearly the same advantages as P2P. It is axiomatic that for drugs of moderate potency and high consumer demand, such as methamphetamine, a synthesis scheme must be relatively straightforward as it must be amenable to the limited expertise available in the clandestine laboratories in order to meet consumer demand.
In this work, only an occasional attempt was made to address the difficulties associated with the practical synthesis of the various derivatives discussed. Some of the compounds discussed do not have conveniently configured precursors that are commercially available. Hence, synthesis of some of these compounds require using the precursors earth, fire, and water. Additionally, as the number and complexity of substitution on any given chemical structure increases, there is a corresponding increase in the number of byproducts and a decrease in the ultimate yield of target compound. In total then, some of the compounds mentioned in this work are not practical, especially considering the clandestine laboratory, given the present state of synthetic knowledge. However, as time moves on, more efficient and direct methods of synthesis will be found and made available to the informed reader through the scientific literature. This point is easily exemplified even by the work of our own forensic scientists (Sy and By 1984; Casale 1987). The clandestine chemist of the future will be more sophisticated than those of the present and compounds not yet conceived of will be within their reach.
Consumer preferences and law enforcement activities are the two dominate forces affecting today's illicit drug markets. While staying within the confines of consumer demand, the clandestine chemist of the future will synthesize those drugs having the highest possible potency in an effort to limit his exposure to law enforcement activities and to expand his illicit business as well.
Acknowledgement: The author wishes to express his appreciation for the invaluable assistance of Dr. Robert Klein, Ann Wimmers, and Charles Harper in the preparation of this article.
ANALGESIC: 1) causing analgesia or freedom from pain. 2) a pain relieving remedy.
ANALOG: Compound with similar electronic structure but different atoms.
CONTROLLED SUBSTANCES: are those drug substances which are listed as of January 1, 1988 under schedules I through V of the United States Title 21 Code of Federal Regulations (CFR) section 1300 to end.
DERIVATIVE: An organic compound containing a structural radical similar to that from which it is derived, for example, benzene derivatives containing the benzene ring.
HOMOLOG: Member of a series of compounds whose structure differs regularly by some radical, for example, methylene, from that of its adjacent neighbors in the series.
SCHEDULE I: Schedule I is a listing of those substances which are controlled under U. S. federal laws, are deemed to have a high potential for abuse, and for which there is no accepted medical use.
SCHEDULE II: Schedule II is a listing of those substances which are controlled under U. S. federal laws, are deemed to have a high potential for abuse, and for which there is a accepted medical use.
Abood, L. C. and Biel, J. H. (1968). The psychotomimetic glycolate esters. In: Drugs Affecting the Central Nervous System. (Burger, A., ad.), l he Medicinal Res. Series, Vol. 2, Dekker, NY, pp. 127. Abood, L. I., Ostfeld, A. and Biel, J. AS. (1959). Structure-activity relationships of 3-piperidyl benzilates with psychotogenic properties, Arch. Int. Pharmacodyn. 120:186. Allen, A. C., Cooper, D. A. and Kram, T. (1981). China white: [alpha]-methylfentanyl, Microgram, 14(3). Alles, C. A. (1959). Neuropharmacology transactions of the Fourth Conference. (Abramson, to. A., ad.) Madison Printing Co., Madison, NJ, pp. 181. Angrist, B. M., Schweitzer, J., Friedhoff, A.J., Hershon, S., Hekimian, L. J. and Floyd, A. (1969). The clinical symptomatology of amphetamine psychosis and its relationship to amphetamine levels in urine, Int. Pharmacopsych. 2:125-139. Anon. (1957) Synthesis of l-Phenylethyl-3-methyl-4- (propananilido)- piperidine [3-methylfentanyl] noted to be a modification of J. (Org. Chem. 12:901, 1947 and ibid. 22:152. Avdovich, H. W., Beckstead, H. D., Dawson, B. A., Ethler, J-C., Latham, D., LeBelle, M., Laurlault, G., Lodge, B. A. and Wilson, W L. (1987). Identification of 4-ethoxy-2,5-dimethoxyam- phetamine HCI (MEM), Microgram 20(3):37-47. Barfknecht, C E. Nichols, D. E. Rusterhole, D. B., Long, J. B., Engelbrecht, J. A., Beaton, M. and Dyer, D. C. (1973;. Potential psychotomimetics: 2-Amino-1,2,3,4-tetrahydronaphthalene, J. Med. Chem. 16:804-808. Beckett, A. H., Casy A. E. Kirk, a. and Walker, J. (1957). Alpha- and beta-prodine type com- pounds: configurational studies, J. Pharm. Pharmacol. 9:939-948. Belleau, B. (l960). The synthesis of (+ -), (+0 and (-) [alpha]- (3-thiamorpholinyl)-benzhydrol, a new selective stimulant of the central nervous system, J. Med. Pharm. Chem. 2:553-562. Benica, W. S. and Wilson, C. O. (1950). Glutarimides I. 3-Alkyl-3-methylglutarimides, J. Am. Pharm. Assoc. 39:451-454. Bentley, K. W:, Hardy, D. C., Crocker, H. P., Had- dlesey D. I. and Mayor, P. A. (1967a). Novel analgesics and molecular rearrangements in the morphine-thebaine group. VI. Base-catalyzed rearrangements in the 6-14-endo-etheno-tetrahy- drothebaine series, J. Am. Chem. Soc. 89:3312. Bentley, K., Hardy, D. G. And Meek, B. (1967b). Novel analgesics and molecular rearrangements in the morphine-thebaine group. II. Alcohols derived from 6,14-endo-etheno- and 6,14-endo- ethanotetra-hydrothebaine, J. Am. Chem. Soc. 89:3273-3280. Berger, L., Ziering, A. and Lee, J. (1947). Piperidine derivatives. IV. 4-alkyl-, 4-cycloalkyl-, and 4- heterocycl-piperidines, J. Org. Chem. 12:901- 910. Biel, J.H., Nuhfer, P A., Hoya, K., Leiser, H. A. and Abood, L. C. (1962). Cholinergic blockage as an approach to the development of new psychotropic agents, Ann. NY Acad. Sci. 96: 251 -262. Boehringer Sohn, C. H. (1960). French patent, # 1,446,523 (Chem. Abstr. 66, 76030t, 1968) and French patent, # 1,446,078 (Chem. Abstr. 66, 76032v, 1968). Boissier, J. R. and Piccard, t: E (1960). Therapie 15:57. Borella, L. E., Langis, A. and Charest, M. P. (1970). Chemistry and pharmacology of new phenyl- isopropylamine anorexiants, Chim. Ther. 5:247- 249. Braun, U. Shulgin, A. T. and Braun, G. (1980a). Centrally active N-substituted analogs of 3,4- methylenedioxyisopropylamine (3,4-methylen- edioxyamphetamine), J. Pharm. Sci. 69(2):192- 195. Braun, U., Shulgin, A. T. and Braun, G. (1980b). Study of the central nervous activity and anagesia of the N-substituted analogs of the amphet- amine derivative, 3,4-methylenedioxyphenyli- sopropyl-amine, Arzneim.-Forsch. 30:825-830. Brossi, A. (1985). Further explorations of unnatural alkaloids, J. Nat. Prod. 48(6):878-893. Brown, C. E (1972). Hallucinogenic Drugs. (Kugel- mass, I.N., ed.), Charles C. Thomas, Spring- field, IL. Burger, A. and Nara, S. (1965. In vitro inhibition studies with homogeneous monoamine oxidases, J. Med. Chem. 8:859. Burger, A. (1970). In: Medicinal Chemistry. Wiley- lnterscience, NY, pp. 1338. Camillo, B. and David, A. (1960). The anticonvul- sant properties of 2-methyl-3-p-bromophenyl- 3H-4-quinazolone hydrochloride and some related compounds, J. Pharm. Pharmacol. 12:501. Casale, J. E (1987). A practical total synthesis of cocaine's enantiomers, Forensic Sci. Int. 33:275- 298. Chen, C. (1958). Pharmacology of 1-(1-phenylcyclo- hexyl)-piperidineHCl, Fed. Proc. 17:358 Clarke, R. L., Daum, S. J., Gambino, A. J., Aceto, M. D., Pearl, J., Levitt, M., Cumiskey, W: R. and Bogado, E. E (/973). Compounds affecting the central nervous system. 4. 3[beta]-phenyltro- pane-2- carboxylic esters and analogs, J. Med. Chem. 16(11):1260-1267. Connell, P H. (1958). Maudsley Monographs Num- ber Five, Oxford University Press, London. Cutting, W. C. (1969). Cutting's Handbook of Phar- macology. Meredith, NY, pp. 512. Daldrup, 7:, Heller, C., Mathiesen, U. Honus, S., Bresges, A. and Haarhoff, K. (1986). Etryptamine, a new designer drug with fatal effects, Z. Rechtsmed. 97(1):61-68. deHaen, P. (1964). dehaen Nonproprietary Name Index with Therapeutic Guide, Vol. 4, Paul deHaen, NY. Dobkin, A. B. (1960). Drugs which stimulate affec- tive behaviour. 2. Comparison of the analeptic effect of d'amphetamine, bemegride with amin- phenazole, methylphenidylacate, iproniazid (micoren) and RP8228, Anaesthesia 15:146-153. Fabing, H. D. (1955). New blocking agent against the development of LSD-25 psychosis, Science 121 :208-210. Franzosa, E. (1985). Solid dosage forms: 1975-1983, J. Forensic Sci. 30(4):1194-1205. Fries, D. S. and Portoghese, P. S. (1976). Stereochem- ical studies on medicinal agents. 20. Absolute configuration and analgetic potency of [alpa]- promedol enantiomers. The role of the C-4 chiral center in conferring stereoselectivity in axial- and equatorial- phenyl prodine congeners, J. Med. Chem. 19(9):1155-1158. Fries, D. S. de Vries, J., Hazelhoff, B. and Horn, A.S. (1986). Synthesis and toxicity toward nigrostriatal dopamine neurons of 1- methyl- 4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) analogues, J. Med. Chem. 29:424-427. Gabriel, S. (1889). Ueber amidomercaptan, Chem. Ber. 22:1137. Gabretcht. W. L. (1959). Synthesis of amides of lysergic acid, J. Org. Chem. 24:368. Garriott, J. C. (1975). Propylhexadrine-a new dan- gerous drug?, Clin. Tox. 8(6):665-666. Gill, E. W., Patron, W. D. M. and Pertwee, R. E. (1970). Preliminary experiments on the chemis- try and pharmacology of cannabis, Nature 228:134-136. Gessner, P. K., McIsaac, W. M. and Page, I. H. (1961). Pharmacological actions of some meth- oxyindolealkylamines, Nature, 190:179-180. Gessner, P. K. and Page, I. H. (1962). Behavior effects of 5-Methoxy- N, N-dimethyltryptamine, other tryptamines and LSD, Amer. J. Physiol. 203:167. Godefroi, E. F., Maddox, V. H., Woods, H. and Parcell, R. F. (1963). Process for Producing a Depressant-like Effect on the Central Nervous System. U. S, Patent # 3,097,136. Goodman, L. S. and Gilman, A. (1970). The Phar- macological Basis of Therapeutics. 4th Edition, The MacMillian Co., London, pp. 646. Govier, W. M., Howes, B. G. and Gibbons, A. J. (1953). The oxidative determination of serotonin and other 3-(beta-aminoethyl)-indoles by mona- mine oxidase and the effect of these compounds on the deaminatin of thramine, Science. 118:596-597. Grimmel, H.W., Guenther, A. and Morgan, J.F. (1946). A new synthesis of 4-quinazolones, J. Am. Chem. Soc. 68:542-543. Gruber, K., Illig, H. and Pflanz, M. (1956). Deut. Med. Wochschr. 81:1130. Grunewald, G.L., Ruth, J.A., Kroboth, T.R., Kamdar, B. V., Patil, P.N. and Salman, K. N. (1976). Conformationally defined adrenergic agents I: Potentiation of levarterenol in rat vas deferens by endo- and exo-2-aminobenzobicyclo [2.2.2]octenes, conformationally defined ana- logs of amphetamine, J. Pharm. Sci. 65(6):920- 923. Haddlesey, D.I., Lewis, J.W., Mayor, P.A. and Young, G.R. (1972). Novel analgesics and molecular rearrangements in the morphine- the- baine group. Part XXIV. 15,16-didehydro-6,14- endo-etheno- 6,7,8,14-tetrahydro-thebaines and -oripavines, J. Chem. Soc. Perkin I pp. 872-874. Hampton, W. H. (1961). Bull. NY Acad. Med. 37:167. Harris, L. S., Clarke, R. L. and Dembinski, J.R (1963). a-Benzyltetrahydrofurfurylamines a new series of psychomoter stimulants. III. The phar- macology of D-threo a-benzyl-N-ethyltetrady- drofurfurylamine (zylofuramine), Arch. Intern. Pharmacodyn. 146:392-405. Harris, S. C. and Worly, R. C. (1957). Analgesic properties of xylopropamine, Proc. Soc. Exp. Biol. Med. 95:212-215. Hartmann, M. and Panizzon, L. (1950). U.S. Patent 2,507,631 to Ciba Pharmaceutical Products Inc. Heer, J., Sury, E. and Hoffmann, K. (1955). Uber alkylenimin- derivate. Piperidin-derivate mit zentralerregender Wirkung II, Helv. Chim. Acta. 38:134-140 Heinzelman, R. V., Anthony, W. C., Lyttle, D. A. and Szmuszkovicz J. (1960). The synthesis of [alpha]-methyltryptophans and [alpha]- alkyl- tryptamines, J. Org. Chem. 25:1548-1558. Heimann, V. H. and Vetter, K (1965) Klinische Unter- suchungen mit einem neuen Psychostimulans (F- 1983), Schweiz. Med. Woch. 95:305-309. Henderson, G. (1986). Designer Drugs: The New Synthetic Drugs of Abuse. In: Proceedings of Controlled Substance Analog Leadership Con- ference. (Church, A. and Sapienza, F., eds.) U. S. Department of Justice, Drug Enforcement Administration, Office of Diversion Control. Henderson, G. L. (1987). Designer Drugs: The Cali- fornia Experience. presented at the Conference on the Technical Aspects of Drug Controll, co- sponsored by the World Health Organization and the Drug Enforcement Administration, Rabat, Morocco. Hochstein, F. A. and Paradies, A. M. (1957). Alka- loids of Banisteria caapr and Prestonia amazoni- cum, J. Am. Chem. Soc. 79:7535. Hodgkins, J. E., Brown, S. D. and Massingill, J. L. (1967). Two new alkaloids in cacti, Tetrahedron Lett. 14:1321-1324. Hollister, L. E. and Friedhoff, A. J. (1966). Effects of 3,4-dimethozyphenylethylamine in man, Nature 210:377-1378. Hollister, L. E. and Gillespie, H. K. (1970). A new stimulant, prolintane hydrochloride, compared with dextroamphelamine in fatigued volunteers, J. Clin. Pharm. 10:103-109. Holmstedt, B., Daly, J. W., Del Pozo, E. C., Horn- ing, E. C., Isbel, H. and Szara, S. (1967). Discussion on the psychoactive action of various tryptamine derivatives. In: Ethnopharmacologic Search for Psychoactive l)rugs. (Efron, D. H., Holmsledt, B. and Kline, N. S., eds.) Public Health Service Publication No. 1645. Hoogsteen, K. and Hirshfield, J. (1983). Thebaine and aetylenic dienophiles, J. Org. Chem. 48:173-177. Hoover and Hass (1947a). Synthesis of paredrine and related compounds, J. Org. Chem. 12:501-505. Hoover and Hass (1947b). Synthesis of 3-amino- 1-phenyl-1-propanoland its methylated deriva- tives, J. Org. Chem. 12:506-509. Horita, A. and Weber, L. J. (1961). Dephosphoryla- tion of psilocybin to psilocin by alkaline phos- phatase, Proc. Soc. Exp. Biol. Med. 106:32. Howell, C. E. Quinor1es, N. Q. and Hardy, R. A. (1962). 2-Amino-2- oxazolin-4-ones. 1. Synthe- sis, J. Org. Chem. 27:1679-1685. Huisgen and Lux (1960). Zum Mechanismus der Phenylhydrazinsynthese nach E. Fischer, Chem. Ber. 93:540. Hurmer, R. and Vernin, (1968) British patent, # 1,093,977, Chem. Abstr. 68, 39648w. Hutchins, C. US, Cooper, C. K., Purro, S. and Rapoport, H. (1981). 6-Demethoxythebaine and its conversion to analgesics of the 6,14- ethenom- orphinan type, J. Med. Chem. 24(7):773-777. Inaba, D. and Brewer, L. (1987). U4EUH, Micro- gram 20(4):55-61. Ippen, H. (1968). Index Pharmacorum-Synonyma, Struktur und Wirkung der organisch-chemis- chen Arzueistoffe. Georg Thieme Verlag, Stutt- gart. Jackman, C. B., Petrov, V. and Stephensen, O. (1960). Some 2,3- disubstituted 3H-4-quinazo- lones and 3H-4-thioquinazolones, J. Pharm. Pharmaco. 12:529-538. Jacob, R. M. and Joseph, N. M. (1960). U. S. Patent, # 2,928,835 to Rhone-Poulene. Jacobs, UR A. and Craig, L. C. (1934). The ergot alkaloids 11. The degradation of ergotinine with alkali, J. Biol. Chem. 24:547-551. Janssen, P A. J. (1960). In: Synthetic Analgesics, Part I. Diphenylpropylamines. Pergamon Press, London. pp. 1-183. Janssen, P A. J. (1961). Pirintramide (R 3365), a potent analgesic with unusual chemical struc- lure, Research Papers, J. Pharm. Pharmaco. (London) 13:513-530. Janssen, R A. (1962a). Chemical features associated with morphine like activity, Anaesthesist 11:1-7. Janssen, P A. (1962b). Review of the chemical fea- tures associated with strong morphine Like activ- ity, Brit. J. Anaesthesia 34:260-268. Janssen, P A. J. and van der Lycken, C. A. M. (1968). The chemical anatomy of potenl mor- phine-like analgesics. In: Drugs Affecting the Central Nervous System. (Burger, A, ed.) Dek- ker, NY, pp. 25-60. Janssen, P. A. J. (1985). The development of new synthetic narcotics. In: Opiods in Anesthesia. (Estafanous, F.G., ed.) Butterworth Publishers, Boston, pp. 37-44. Jordan, P. (1986). Hallucinogenic amphetamine investigations. In: Proceedings Of Controlled Substance Analog Leadership Conferellces (Sapienza, E L. and A.C. Church, A. C., eds.) U. S. Dept. of Justice, I)rug Fnlolcellle Administration . Joshi, K. C. and Singh, V. K. (1973). Fluorinated quinazolanes. Part I Synthesis and pharmalogi- cal activity of some fluorinated 2-alkyl-3-aryl- 4(3H)-quanazolones and the corresponding thioquanazolones, Indian J. Chem. 11:430-432. Joshi, K. C. and Singh, V. K. (1974). Fluorinated quinazolones: effect of some fluorinated 2-alkyl- 3-aryl-4(3H)-quinazolones and thioquanazolo- nes on pyruvic acid oxidation, Indian .1. Exp. Biol. 12:286-287. Joshi, K. C., Singh, V. K., Mehta, D. S., Sharma, K. C. and Gupta, L. (1975). Fluorinated quinazo- lones III: Synthesis and CNS depressant activity of fluorinated quinazolone derivatives, J. Pharm. Sci. 64:1428-1430. Kalir, A. and Pelah, Z. (1967). 1-Phenylcycloalky- lamine derivatives. I, Israel J. Chem. 5:223-229. Kalir, A., Edery, H., Pelah, Z., Balderman, D. and Porath, G. (1969). 1-Phenylcycloalkylamine derivatives. II. Synthesis and pharmacological activity, J. Med. Chem. 12:473-477. Kisakurek, M. V. and Hesse, M. (1980). Chemotax- onomic studies of the apocynaceae, loganiaceae, and rubiaceae, with reference to indole alka- loids. In: The Annual Proceedings of the Phy- tochemical Society of Europe Number 17, (Phillipson, J.D. and Zenk, M. H., eds.) Aca- demic Press, NY, pp. 11. Klein, D. F. and Davis, J. M. (1969). Diagnosis and Drug Treatment of Psychiatric Disorders, Williams and Wilkins Co., Baltimore, MD. Knoll, J., Vizi, E. S. and Ecseri, Z. (1966). Psycho- mimetic methylamphetamine derivatives, Arch. Int. Pharmacodyn. 159:442-451. Kornfeld, E. C., Fornefeld, E. J., Kline, G. B., Mann, M. G., Jones, R. C. and Woodward, R. B. (1954). The total synthesis of lysergic acid and ergonovine, J. Am. Chem. Soc. 76:5256. Lachman, L. and Malspeis, L. (1962). U. S. Patent, # 3,060,089 to Ciba Pharmaceutical Products Inc. Langston, J. W, Bailard, P., Tetrud, J. W. and Irwin, I. (1983). Chronic Parkinsonism in humans due to a product of meperidine- analog synthesis, Science 219:979-980. Langston, J. W. and Rosner, D. J. (1986). The hazards and consequences of the designer drug phenom- enon: An initial approach to the problem. In: Proceedings of Controlled Substance Analog Leadership Conference, (Church, A. C. and Sapienza, F.L. Lathrap, D. W. (1976). Ancient Ecuador Culture, Clay and Creativity, 3000-300 B.C., Chicago, IL: Field Museum of Natural History. Liddell, D. W. and Weil-Malherbe, H. (1953). The effects of methedrine and of lysergic acid dieth- ylamide on mental processes and on the blood adrenaline level, J. Neurol. Neurosurg. Psychiat. 16:7-13. Loew, G. H. and Jester, J. R. (1975). Quantum chemical studies of meperidine and prodine, J. Med. Chem. 18(11):1051-1056. Maddox, V. H., Godefroi, E. F. and Parcell, R. F. (1965). The synthesis of phellcyclidine and other 1-arylcyclohexylamines, J. Med. Chem. 8:230- 235. Mannich, and Jacobsohn (1910). Uber oxyphenyl- alkylamine und dioxyphenyl-alkylamine, Chem. Ber. 43: 189. Markey, S. P., Castagnoli, N., Kopin, I. and Trevor, A. (198S. In: MPTP-a Neurotoxin Producing a Parkinsonian Syndrome. Academic Press, NY. Marsh, D. F. and Herring, D. A. (1950). The phar- macological activity of the ring methyl substi- tuted phenisopropylamines, J. Pharmacol. Exp. Ther. 100:298-308. McCarty, F. J., Tilford, C. H. and Van Campen, M. G. (1957). Central stimulants. [alpha],[alpha]- disubstituted 2-piperidinemethanols and 1,1-dis- ubstituted heptahydrooxazolo[3,4-a]pyridines, J. Am. Chem. Soc. 79:472-480. McGlothlin, W. H. (1971). Amphetamines, Barbitu- rates, and Hallucinogens: An Analysis of Use, Distribution and Control. SCID-TR-2, United States Department of Justice, Drug Enforcement Administration, pp. 98. Meier, R., Gross, F. and Tripod, J. (1954). Klim. Wochschr. 32:445. Naranjo C., Shulgin, A. T. and Sargent, T. (1967). Evaluation or 3,4 methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy, Med. Pharmacol. Exp. 17:359-364. Naranjo, C. (1967). In: Ethnopharmacological Search for Psychoactive Drugs. (Holmstedt, B., ed.) Department of Health, Education, and Wel- fare, Washington, DC, pp. 385-391. Nied, J. and Smith, R. M. (1982). Identification of fencamfamine, Microgram 15(10):168-172. Otto, W. G. (1956). Angew. Chem. 68:181. Parke, Davis & Co. (1960). Brit. Pat. #836,083. Parke, Davis & Co. (1963). U. S. Pat. #3,097,136. Patil, P. N. and Yamauchi, D. (1970). Influence of the optical isomers of some centrally acting drugs on norepinephine responses, Eur. J. Pharmacol. 12(1):132-135. Peterson, R. C. and Stillman, R. C. (1978). Phencyc- lidine (PCP) Abuse: An Appraisal. NIDA Research Monograph #21, National Institute on Drug Abuse, Rockville, MD. Parkes, D. (1986). In: MPTP and the Aetiology of Parkinson's Disease. J. Neural Trans. Sup. 20. Springer-Verlag, NY. Petersen, S., Tietze, E., Hoffmeister, E. and Wirth, W. (1963). British patent, # 932,680. Portoghese, P. S. and Malspeis, L. (1961). Relative hydrolytic rates of certain alkyl (b) dl-[alpha] (2-Piperidyl)-phenylacetates, J. Pharm. Sci. 50:494-501 . Riley, T. N., Hale, D. B. and Wilson, M. C. (1973). 4-Anilidopiperi- dine analgesics I. Synthesis and analgesic activity of certain ring-methylated 1- substituted 4-propananilidopiperidines, J. Pharm. Sci. 62(6):983-986. Robie, T. R. (1961). A new and safer monoamine oxidase inhibitor, J. Neuropsychiat. 2:(Suppl. 1) 531-48. Robinson, B. (1983). The Fischer Indole Synthesis, Wiley, NY. Robinson, T. (1968). The Biochemistry of Alkaloids, Verlag, NY, pp. 77. Rometsch, R. (1958). U. S. Patent, # 2,838,519 to Ciba Pharmaceutical Products Inc. Rometsch, R. (1960). U. S. Patent, # 2,957,880 1, Ciba Pharmaceutical Products Inc. Rosengarten, E (1969). The Book of Spices, Living ston Publishing Company, Philadelphia, PA, pp. 369-372. Rothlin, E. (1957a). Lysergic acid diethylamide and related substances, Ann NY Acad. Sci. 66:668. Rothlin, E. (1957b). Pharmacology of LSD, .1 Pharm. Pharmacol. 9:569. Schaeffer, J. C., Cho, A. K., Glenn, T. N. and Glenn, S. T. (1975). Inhibition of synaptosomal accu- mulation of l-norepinephrine I: N.- arylalkyl and N-aryloxyalkyl dl-amphetamines and related compounds, J. Pharm. Sci. 64(9):1462-1469. Schneider, J. A. and Siggs, E. B. (1957). Neurophar- macological studies on ibogaine, an indole alka- loid with central-stimulant properties, Ann. NY Acad. Sci. 66:765-776. Scholz, K. and Panizzon, L. (1954). Uber die darstel- lung von pyridyl- und piperidyl-aryl-acetonitrilen und einigen Umwandlungs-produkten, Helv. Chim. Acta. 37:1605. Schultes, R. E. (1938). The Appeal of Peyote (Lopho- phora williamsii) as a medicine, Am. Anthropol. 40:698-715. Schultes, R. E. (1940). The aboriginal therapeutic uses of Lophophora williamsii. Cactus Succulent J. 12:177-181. Sheppard. H., Tsien, W. H., Rodegker, W. and Plummer, A. J. (1960). Distribution and elimi- nation of methylphenidate-C14, Toxicol. Appl. Pharmacol. 2:353-362. Shoemaker, D. W, Bidder, T. G., Boettger, H. G., Cummins, J. T. and Evans, M. (1979). Com- bined gas chromatography and mass spectrome- try of aromatic B-carbolines, J. Chromatogr. 174:159-164. Shulgin, A. T. (1964). Psychotomimetic amphet- amines: methoxy 3,4-dialkoxyamphetamines, Experientia 20:366. Shulgin, A. T. (1969). Psychotomimetic agents related to the catecholamines, J. Psychedelic Drugs. 2(2):14-19. Shulgin, A. T., Sargent, T. and Naranjo, C. (1969). Structure-activity relationships of one-ring psy- chotomimetics, Nature 221:537-541. Shulgin, A. T. (1970). Psychotomimetic Drugs. (Efron, D.H., ed.) Raven, NY. Shulgin, A. T. (1975). Drugs of abuse in the future, Clin. Tox. 8(4):405-456. Smissman, C. E and Pazdernik, T. L. (1973). A conformational study of phenethylamine recep- tor sites. 1. Syntheses of semirigid analogs of [beta]-methylamphetamine, J. Med. Chem. 16: 14-18. Smith, S. (1927). 1-Methylephedrine, an alkolyd from ephedra species, J. Chem. Soc. 2056-2059. Smythies, J. R., Johnston, V. S. and Bradley, R. J. (1969). Behavioural models of psychosis, Brit. J. Psychiat. 115:55-68. Snyder, S. H. and Richelson, E. (1970). Steric models of drugs predicting psychedelic activity. In: Psy- chotomimetic Drugs. (Efron, D., ed.) Raven, NY, pp. 43. Spalla, C. (1980). Production of ergot alkaloids by fermentation. In: The Annual Proceedings of the Phytochemical Society of Europe Number 17, (Phillipson, J.D. and Zenk, M.H., eds.) Academic Press, NY, pp. 273-283. Spath, E. (1919). Uber die Anhalonium-alkaloids I. Anhalin und Mezcalin, Mh Chem. 40:129. Speeter, M. E. and Anthony, W. C. (1954). The action of oxalyl chloride on indoles: A new approach to tryptamines, J. Am. Chem. Soc. 76:62()8-621(). Sumitomo Chemical Company (1968). British patent, # 1,054,718 Chem. Abstr. 66, 76031u. Sury, E. and Hoffmann, K. (1954). Uber Alkylen- imin-derivate. Piperidin-derivate mit zentralerre- gender Wirkung I, Helv. Chim. Acta. 37:2133- 2145. Sy, W-W. and By, A. W (1984). A more efficient synthesis of 2,3,5-trimethoxyamphetamine using nitryl iodide, NO21, Microgram 17(12):179-191. Szara, S. and Hearst, E. (1962). The 6-hydroxylation of tryptamine derivatives. A way of producing psychoactive metabolites, Ann. NY Acad. Sci. 96: 134. Szara, R., Rockland, L. H., Rosenthal, D. and Handlon, J. H. (1966). Psychological effects and metabolism of N,N-diethyltryptamine in man, Arch. Gen . Psychiat . 15: 321. Szara, S. (1970). DMT (N,N-dimethyltryptamine) and homologues: Clinical and pharmacological considerations. In: Psychotomimetic Drugs. (Efron, D., ed.) Raven, NY, pp. 275. Thole, E B. and Thorpe, J. E (1911). The formation and reactions of amino-compounds. Part XV. The production amino-derivatives of peperidine leading to the formation of B-disubstituted glu- taric acids, J. Chem. Soc. 99:422-448. Tilford, C. H. and Van Campen, M. C. (19S4). Diuretics. [alpha],- [alpha]-disubstituted 2-pipe- ridine-ethanols and 1,3-disubstituted octa- hydropyrid[1,2-c]oxazines, J. Am. Chem. Soc. 76:2431. Tilford, C. H., Shelton, R. S. and Van Campen, M. G. (1948). Histamine antagonists. Basically sub- stituted pyridine derivatives, J. Am. Chem. Soc. 70:4001-4008. Traube, W. and Ascher, R. (1913). Uber das isohy- dantoin 2-imino- 4-keto-tetrahydro-oxazol und seine Homologen, Chem. Ber. 46:2077. Treptow, K. R., Affleck, D. C., Roehl, C. A. and Soelling, W. M. (1963). Nylidrin hydrochloride in senile arteriosclerosis, Arch. Neurol. 9:142- 146. Tripod, J., Bein, H. J. and Meier, R. (1954a). Char- acterization of central effects of serpasil (reser- pin, a new alkaloid of Rauwolfia serpentina B.) and of their antagonistic reactions, Arch. Intern. Pharmacodyn. 96:406-425. Tripod, J., Sury E. and Hoffmann, K. (1954b). Zentralerregende Wirkung eines neven Pipe- ridinderivates, Experientia 10:261-262. Turner, W. J. (1963). Experiences with primary proc- ess thinking, Psychiatr. Q. 37:476-488. Turner, W. J., Merlis, S. and Carl, A. (1955). Con- cerning theories of indoles in schizophrenigene- sis, Am. J. Psychiat. 112:466-467. Usdin, E. and Efron, D. H. (1972). Psychotropic Drugs and Related Compounds, 2nd edition, Department of Health, Education, and Welfare, Rockville, MD. Van Bever, W. F. Niemegeers, C. J. E. and Janssen, P. A. J. (1974). Synthetic analgesics. Synthesis and pharmacology of the dia- stereoisomers of N-[3-methyl-1-(2-phenylethyl)-4-piperidyl] -N- phenylpropanamide and N-[3-methyl-1-(1- methyl-2-phenylethyl)- 4-piperidyl]-N-phenylpro- panamide, J. Med. Chem. 17:1047-1051. Van Daele, P. G. H., De Bruyn, M. F. L., Boey, J. M., Sanczuk, S., Agten, J. T. M. and Janssen, P A. J. (1976). Synethic analgesics: N-(1-[2-arylethyl]- 4-substituted 4-piperidinyl) N-arylalkanamides. Aezneim.-Forsch, (Drug Res.) 26(8):1521-1529. Weisz, I. and Dudas, A. (1960). Uber Stereoisomere 2-Piperidylphenylessigsaure-methylester, Monat- shefte fur Chemie 91:840-849. Werner, H. W. and Tilford, C. H. (1953). U. S. Patent, # 2,624,739 to the Wm. S. Merrell Co. Whaley, W. M. and Govindachari, T. R. (1951). Organic Reactions. Vol 6. Wiley, NY, pp. 151 190. Wilimowski, M. (1962). Arch. Immunol. Terappii Doswiadczalnej. 10:739. Winthrop, S. O. and Humber, L. G. (1961). Central stimulants. Cyclized diphenylisopropylamines J. Org. Chem. 26:2834-2836. Wooley, D. W. (1962). The Biochemical Bases of Psychoses or the Serotonin Hypothesis about Mental Disease, John Wiley & Sons, NY. Zbinden, G., Randall, L. O. and Moe, R. A. (1960). Dis. of Nerv. Sys. 21:89. Ziering, A. and Lee, J. (1947). Piperidine derivatives V. 1,3- Dialkyl-4-aryl-4-acyoxypiperidines, J. Org. Chem. 12:911-914. Ziering, A., Motchane, A. and Lee, J. (1957). Pipe- ridine derivatives. IV. 1,3-Disubstituted-4-aryl- 4-acyloxy piperidines, J. Org. Chem. 22:1521 1528.